Review of implant gonadotrophin-releasing hormone agonist use: experience in a single academic center

Background: Gonadotrophin-releasing hormone agonists (GnRHa) are used for puberty suppression in central precocious puberty (CPP) and gender dysphoria (GD). Guidelines on biochemical monitoring are not defined. Objectives: To evaluate the utility of biochemical monitoring of GnRHa therapy in patients with CPP or GD.Methods: Retrospective chart review of patients 18 years or younger who received GnRHa therapy from 1/1/2018 to 3/2/2021. Results: 103 patients were evaluated, 43 with CPP and 60 with GD. Using thresholds of basal luteinizing hormone (LH) <2 IU/L and stimulated LH <4 IU/L, biochemical pubertal suppression occurred in all but two patients. Basal LH frequently remained above prepubertal range.Conclusions: Laboratory assessment for puberty suppression on GnRHa therapy may be unnecessary in CPP and GD patients monitored with physical exams.